We recently published a list of 12 Best Quality Stocks to Invest in Now. In this article, we are going to take a look at ...
Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...
As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...
"Billionaire" and "successful hedge fund manager" are titles that carry significant weight on Wall Street. These and others ...
StockStory.org on MSN1d
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals StocksAs the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
1d
Zacks Investment Research on MSNNVO Stock Slips 4% as Roche Inks Obesity Drug Deal With ZealandNovo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...
GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...
Access to Compounded GLP-1s Is Drying Up. Here’s What to Know About the Copycat Weight-Loss Drugs.
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...
Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results